The last days of the year are decisive for Bavarian Nordic’s dream of breaking even on their 2022 operating profit, says Henrik Juuel, chief financial officer at the vaccine company, to Marketwire.

Bavarian publishes its guidance as an interval because annual revenue is dependent on timing of order shipments. Thus, he dares not jinx the ’breakeven’ dream for this year while orders are still being shipped from Bavarian’s product facilities.

”I can’t comment it directly being that these last days at the end of the year are decisive for our revenue. It’s also pretty crucial which costs come in — especially since we are conducting some expensive trials at the moment. There’s still a pretty good chance that we’ll end up in the upper end of our guidance,” says Juuel.

Bavarian Nordic’s latest guidance adjustment from September eyed earnings before interest, taxes, depreciations and amortizations between DKK 0 and DKK -200m (USD -28.6m).

At the beginning of the year, that zero was not even within reach, however the monkey pox outbreak resulted in several advances for the company, and the latest included the possibility of breaking even.

According to Juuel, there’s a lot of work put in right before Christmas, whereas the days between Christmas and New Year’s are more quiet. However, every day is decisive and so far everything is going according to plan, despite reports of supply chain under pressure this holiday season.

”Everything is going according to plan. There’s been some logistic challenges and there always is. It’s just ’business as usual’,” Juuel says.

Bavarian Nordic’s initial financial outlook for this year forecast an operating deficit of DKK 1bn to 1.3bn (USD 143-186m)

Analyst: New Bavarian Nordic deal is a sign of governments’ watchful eye on virus threats

Bavarian Nordic enters agreement with US defense department

Bavarian Nordic meets recruitment target for RSV study